267 related articles for article (PubMed ID: 28953735)
21. Rethinking the one-size-fits-most approach to venous thromboembolism prophylaxis after radical cystectomy.
Corona LE; Singhal U; Hafez K; Herrel LA; Kaffenberger SD; Montgomery JS; Morgan TM; Weizer AZ; Qin Y; Ambani SN
Urol Oncol; 2020 Oct; 38(10):797.e1-797.e6. PubMed ID: 32624425
[TBL] [Abstract][Full Text] [Related]
22. A Weight- and Anti-Xa-Guided Enoxaparin Dosing Protocol for venous thromboembolism Prophylaxis in intensive care unit Trauma Patients.
Bigos R; Solomon E; Dorfman JD; Ha M
J Surg Res; 2021 Sep; 265():122-130. PubMed ID: 33930618
[TBL] [Abstract][Full Text] [Related]
23. Weight-based enoxaparin dosing for venous thromboembolism prophylaxis in the obese trauma patient.
Bickford A; Majercik S; Bledsoe J; Smith K; Johnston R; Dickerson J; White T
Am J Surg; 2013 Dec; 206(6):847-51, discussion 851-2. PubMed ID: 24070664
[TBL] [Abstract][Full Text] [Related]
24. Weight-Based Enoxaparin Achieves Adequate Anti-Xa Levels More Often in Trauma Patients: A Prospective Study.
Stutsrim AE; Eady JM; Collum M; Rebo GJ; Rebo KA; Miller PR; Nunn AM
Am Surg; 2021 Jan; 87(1):77-82. PubMed ID: 32915054
[TBL] [Abstract][Full Text] [Related]
25. Prophylactic Enoxaparin Adjusted by Anti-Factor Xa Peak Levels Compared with Recommended Thromboprophylaxis and Rates of Clinically Evident Venous Thromboembolism in Surgical Oncology Patients.
Kramme K; Sarraf P; Munene G
J Am Coll Surg; 2020 Mar; 230(3):314-321. PubMed ID: 31843692
[TBL] [Abstract][Full Text] [Related]
26. Fixed-dose enoxaparin after bariatric surgery: the influence of body weight on peak anti-Xa levels.
Celik F; Huitema AD; Hooijberg JH; van de Laar AW; Brandjes DP; Gerdes VE
Obes Surg; 2015 Apr; 25(4):628-34. PubMed ID: 25223871
[TBL] [Abstract][Full Text] [Related]
27. The ATLANTIC study: Anti-Xa level assessment in trauma intensive care.
Rakhra S; Martin EL; Fitzgerald M; Udy A
Injury; 2020 Jan; 51(1):10-14. PubMed ID: 31679829
[TBL] [Abstract][Full Text] [Related]
28. Weight-Based Dosing for Low-Molecular-Weight Heparin (Enoxaparin) Administration to Achieve Optimal VTE Prophylaxis in Trauma Patients.
Thind T; Heye T; Henson C; Reif R; Jensen HK; Kalkwarf KJ; Bhavaraju A; Robertson R; Jenkins A
Am Surg; 2024 Jun; 90(6):1406-1411. PubMed ID: 38518208
[TBL] [Abstract][Full Text] [Related]
29. Optimal Dosing of Prophylactic Enoxaparin after Surgical Procedures: Results of the Double-Blind, Randomized, Controlled FIxed or Variable Enoxaparin (FIVE) Trial.
Pannucci CJ; Fleming KI; Bertolaccini C; Agarwal J; Rockwell WB; Mendenhall SD; Kwok A; Goodwin I; Gociman B; Momeni A
Plast Reconstr Surg; 2021 Apr; 147(4):947-958. PubMed ID: 33761517
[TBL] [Abstract][Full Text] [Related]
30. Relation of antifactor-Xa peak levels and venous thromboembolism after trauma.
Karcutskie CA; Dharmaraja A; Patel J; Eidelson SA; Martin AG; Lineen EB; Namias N; Schulman CI; Proctor KG
J Trauma Acute Care Surg; 2017 Dec; 83(6):1102-1107. PubMed ID: 29190255
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of an enoxaparin dosing calculator using burn size and weight.
Faraklas I; Ghanem M; Brown A; Cochran A
J Burn Care Res; 2013; 34(6):621-7. PubMed ID: 24043245
[TBL] [Abstract][Full Text] [Related]
32. Comparison of postpartum anti-Xa levels following enoxaparin administration to prevent venous thromboembolism using 2 weight-based protocols: a randomized controlled trial.
Haj R; Massalha M; Eitam H; Kassabri R; Yefet E; Nachum Z
Am J Obstet Gynecol MFM; 2023 Aug; 5(8):100988. PubMed ID: 37156466
[TBL] [Abstract][Full Text] [Related]
33. Enoxaparin dose adjustment is associated with low incidence of venous thromboembolic events in acute burn patients.
Lin H; Faraklas I; Saffle J; Cochran A
J Trauma; 2011 Dec; 71(6):1557-61. PubMed ID: 22027887
[TBL] [Abstract][Full Text] [Related]
34. Anti-Xa guided enoxaparin dose adjustment improves pharmacologic deep venous thrombosis prophylaxis in burn patients.
Cronin BJ; Godat LN; Berndtson AE; Pham A; Kolan S; Box K; Lee JG; Costantini TW
Burns; 2019 Jun; 45(4):818-824. PubMed ID: 30827851
[TBL] [Abstract][Full Text] [Related]
35. Prospective comparison of three enoxaparin dosing regimens to achieve target anti-factor Xa levels in hospitalized, medically ill patients with extreme obesity.
Freeman A; Horner T; Pendleton RC; Rondina MT
Am J Hematol; 2012 Jul; 87(7):740-3. PubMed ID: 22565589
[TBL] [Abstract][Full Text] [Related]
36. Increased enoxaparin dosing is required for obese children.
Lewis TV; Johnson PN; Nebbia AM; Dunlap M
Pediatrics; 2011 Mar; 127(3):e787-90. PubMed ID: 21321026
[TBL] [Abstract][Full Text] [Related]
37. Implementation of an enoxaparin protocol for venous thromboembolism prophylaxis in obese surgical intensive care unit patients.
Ludwig KP; Simons HJ; Mone M; Barton RG; Kimball EJ
Ann Pharmacother; 2011 Nov; 45(11):1356-62. PubMed ID: 22009998
[TBL] [Abstract][Full Text] [Related]
38. Association of Anti-Factor Xa-Guided Dosing of Enoxaparin With Venous Thromboembolism After Trauma.
Karcutskie CA; Dharmaraja A; Patel J; Eidelson SA; Padiadpu AB; Martin AG; Lama G; Lineen EB; Namias N; Schulman CI; Proctor KG
JAMA Surg; 2018 Feb; 153(2):144-149. PubMed ID: 29071333
[TBL] [Abstract][Full Text] [Related]
39. Impact of Weight on Anti-Xa Attainment in High-Risk Trauma Patients on Enoxaparin Chemoprophylaxis.
Farrar JE; Droege ME; Philpott CD; Mueller EW; Ernst NE; Makley AT; Deichstetter KM; Droege CA
J Surg Res; 2021 Aug; 264():425-434. PubMed ID: 33848842
[TBL] [Abstract][Full Text] [Related]
40. Achievement of goal anti-Xa activity with weight-based enoxaparin dosing for venous thromboembolism prophylaxis in trauma patients.
Taylor A; Huang E; Waller J; White C; Martinez-Quinones P; Robinson T
Pharmacotherapy; 2021 Jun; 41(6):508-514. PubMed ID: 33864688
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
